Chengdu Easton Biopharmaceuticals Co., Ltd.

Chengdu Easton Biopharmaceuticals Co., Ltd. saw a notable stock decline today, contrasting with the broader market's gains. Despite a strong annual return, the company reported a decrease in profits and faced challenges in recent weeks. Its financial metrics indicate a solid balance sheet and ongoing market navigation.

Chengdu Easton Biopharmaceuticals Co., Ltd. has experienced a change in its stock valuation grade, now reflecting a fair assessment. Key financial metrics include a P/E ratio of 44 and a dividend yield of 0.51%. Despite recent positive quarterly performance, long-term growth has been modest.

Chengdu Easton Biopharmaceuticals Co., Ltd. has shown strong stock performance, gaining 7.05% on March 27, 2026, and achieving a 105.77% increase over the past year. The company has a market capitalization of CNY 11,367 million and reported solid operational metrics, including a peak operating cash flow of CNY 335.41 million.

Chengdu Easton Biopharmaceuticals Co., Ltd. has seen a notable rise in its stock today, contrasting with the broader market. Over the past year, the company has achieved substantial growth, outperforming the China Shanghai Composite. It maintains strong financial metrics, including robust cash flow and a low debt-equity ratio.

Chengdu Easton Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite recent short-term challenges, the company has achieved strong long-term growth, with an 85.35% increase over the past year and a market capitalization of CNY 11,367 million.

Chengdu Easton Biopharmaceuticals Co., Ltd. has seen a notable rise in stock performance, achieving an intraday high and demonstrating strong weekly and yearly gains. The company reported robust operating cash flow and a decrease in raw material costs, indicating a solid position within the Pharmaceuticals & Biotechnology sector.

Chengdu Easton Biopharmaceuticals Co., Ltd. has seen a significant increase today, contrasting with the modest rise of the China Shanghai Composite. Over the past year, the company has outperformed the broader market, although it has faced recent challenges. It maintains a strong market capitalization and a notable dividend yield.

Chengdu Easton Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market. Despite recent losses, the company has shown strong long-term growth, with impressive annual returns and solid financial metrics, including positive operating cash flow and a low debt-equity ratio.